The Road Ahead: KRAS Inhibition, Treatment Sequencing, and Practical Implementation of Emerging Therapies

The final segment looks toward the future of mPDAC management, with a focus on the evolving role of KRAS inhibition across lines of therapy. The ongoing RASolute 303 trial evaluating daraxonrasib alone and in combination with chemotherapy in the first-line setting is discussed, along with its potential expansion into adjuvant and perioperative contexts. Key unanswered questions around sequencing, including when to use codon-specific versus pan-RAS inhibitors and whether combination strategies outperform monotherapy, are outlined as the field's most pressing priorities. Practical guidance is offered for community oncologists implementing NALIRIFOX without full academic infrastructure, emphasizing patient education, chemotherapy nursing support, and proactive side effect management. Physicians also flag a learning curve ahead with novel KRAS inhibitor toxicities, particularly rash, as the field prepares to integrate daraxonrasib and other emerging agents into routine clinical care.